EGFR and non-small cell lung carcinoma: In particular, MET TKD mutations were identified in 32 treatment-naïve NSCLC patients (cohort 1), 41 MET-TKI-treated patients (cohort 2), and 13 EGFR-TKI-treated patients (cohort 3).